Psychedelics Company Takes 'A Key Step' With New Formulation Of Its Psilocin Prodrug For Anxiety
Portfolio Pulse from Vuk Zdinjak
Enveric Biosciences (NASDAQ:ENVB) has developed an improved formulation of its psilocin prodrug EB-373 for anxiety disorder treatment. The optimized, phase 1-ready formulation utilizes a novel salt form, enhancing scalability, stability, and delivery for ongoing preclinical studies and planned clinical development.
June 26, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has developed an improved formulation of EB-373, its lead product candidate for anxiety disorder treatment, which is expected to enhance scalability, stability, and delivery.
The improved formulation of EB-373 is a significant development for Enveric Biosciences as it enhances the drug's scalability, stability, and delivery. This will support ongoing preclinical studies and planned clinical development, potentially leading to faster progress towards commercialization. As a result, this news is likely to have a positive short-term impact on Enveric's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100